Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche Touts Safety Profile For NMOSD Drug Satralizumab

Approvals Sought For Rare Disorder

May 22 2020

• By Kevin Grogan

Blue man — Rare: NMOSD affects 10,000 people in Europe, • Source: Shutterstock

Related Content

Alexion Win Thwarts Roche’s EU Fast-Track Hopes

Feb 21 2020

Alexion's Soliris To Treat EU Patients With NMOSD

Aug 28 2019

Related Companies

Roche Holding AG

Alexion Pharmaceuticals Inc.

Viela Bio, Inc.

Additional Topics

Rare Diseases Clinical Trials Companies Safety Research & Development Neurology BioPharmaceutical

More from Neurological

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.